Eurograd message

--Apple-Mail=_A7BB10FE-EE25-4115-9CD8-977ED7947FC6 Content-Transfer-Encoding: quoted-printable Content-Type: text/plain; charset=us-ascii

Dear all,

We invite contributions to our open panel 004.The futures of and in = Genomics at = the 2022 EASST Conference in Madrid (July 6-9). Convened by Violeta = Argudo-Portal and Mauro Turrini (Institute of Public Goods and Policies, = Spanish National Research Council).

Abstract: The dramatic fall in the price and cost of genomics testing has made = possible a practice that seemed to be confined to the laboratory until a = few years ago. Testing one's DNA, or that of beings close to us is an = increasingly widespread and almost trivialised possibility. Particularly = in the reproductive sphere, where non-invasive prenatal testing, = pre-conception or gamete donor screening are emerging, but also more = simply with the use of direct-to-consumer genetic tests that can = investigate susceptibility to diseases, food intolerances, allergies, = and so on. A common element of these tests is that they use genomics to = anticipate the future in different ways: to predict the possibility of a = genetic mutation in a couple before conception, to identify the presence = of a chromosomal/genetic disorders in a foetus before it to be born, or = the predisposition to a common, multi-factorial disease before its = onset. The relationship with the future is certainly one of the aspects = that makes genomics as much promising as controversial, if not even = disturbing. That is why this panel aims to ignite a conversation around = the question: what are the futures embedded in genomics?=20 The possibility of a disease-free future comes along with the threat of = discriminating on the basis of DNA and, more generally, with the = imperative of knowledge-based management to optimise risk. While = healthcare systems are extremely cautious about these tests, whose = clinical usefulness they often dispute, their main driving forces are = clinics, laboratories, or private companies whose commercial strategies = rely on the symbolic power of the genome. In this space, situated on the = fringes or outside the national healthcare services or the medical = establishment, the access rules to human constitutional DNA are = reconfigured and rooted in the very materiality of the technology used. = These types of highly routinised testing practices make use of a wide = range of devices that, for instance, analyse genomes through panels of = pre-set DNA variants or segments in a quasi-automatized way. As these = panels incorporate the medical decision of what regions of DNA are worth = being analysed, they are the object of debate of international, = national, or local ethics committees, and medical associations. Also, = like many other classification systems, they tend to crystallize into = standards that compete in crafting the future of genomics. In this = panel, we welcome contributions aiming to explore how these futures = embedded in genomics reconfigure practices of consumption and = subjectification, discourses and imaginaries of health and well-being, = systems of regulation of access to DNA, and the production of testing = devices. We are also open to submissions delving into the = more-than-human confines, where genetic testing or screening are used on = embryos, foetuses, or non-human animals such as companion animals or = farm animals.=20

Deadline: February 1st.=20

Information about the call for submissions can be found here: = https://easst2022.org/callforsubmissions.asp and the full abstract here: = https://easst2022.org/IMAGENES/panelsResultados/004.pdf

Contact person: violeta.argudo@csic.es (Violeta Argudo-Portal).

With best wishes, Violeta Argudo-Portal and Mauro Turrini

--Apple-Mail=_A7BB10FE-EE25-4115-9CD8-977ED7947FC6 Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset=us-ascii

Dear = all,We invite = contributions to our open panel 004.The futures of and in Genomics at the 2022 EASST = Conference in Madrid (July 6-9). Convened by Violeta Argudo-Portal = and Mauro Turrini (Institute of Public Goods and = Policies, Spanish National Research = Council).Abstract:The dramatic fall in the price and cost of genomics testing has made = possible a practice that seemed to be confined to the laboratory until a few years = ago. Testing one's DNA, or that of beings close to us is an increasingly = widespread and almost trivialised possibility. Particularly in the reproductive = sphere, where non-invasive prenatal testing, pre-conception or gamete donor = screening are emerging, but also more simply with the use of direct-to-consumer = genetic tests that can investigate susceptibility to diseases, food = intolerances, allergies, and so on. A common element of these tests is that they use genomics to anticipate the future in different ways: to predict the possibility of a = genetic mutation in a couple before conception, to identify the presence of a chromosomal/genetic disorders in a foetus before it to be born, or the predisposition to a common, multi-factorial disease before its onset. = The relationship with the future is certainly one of the aspects that makes genomics as = much promising as controversial, if not even disturbing.  That is why this panel = aims to ignite a conversation around the question: what are the futures embedded in = genomics? The possibility of a disease-free future comes along with the threat of discriminating on the basis of DNA and, more generally, with the = imperative of knowledge-based management to optimise risk. While healthcare systems = are extremely cautious about these tests, whose clinical usefulness they = often dispute, their main driving forces are clinics, laboratories, or private companies whose commercial strategies rely on the symbolic power of the = genome. In this space, situated on the fringes or outside the national = healthcare services or the medical establishment, the access rules to human = constitutional DNA are reconfigured and rooted in the very materiality of the = technology used. These types of highly routinised testing practices make use of a wide = range of devices that, for instance, analyse genomes through panels of pre-set DNA = variants or segments in a quasi-automatized way. As these panels incorporate the = medical decision of what regions of DNA are worth being analysed, they are the = object of debate of international, national, or local ethics committees, and = medical associations. Also, like many other classification systems, they tend to = crystallize into standards that compete in crafting the future of genomics. In this = panel, we welcome contributions aiming to explore how these futures embedded in genomics reconfigure practices of consumption and subjectification, = discourses and imaginaries of health and well-being, systems of regulation of = access to DNA, and the production of testing devices. We are also open to = submissions delving into the more-than-human confines, where genetic testing or = screening are used on embryos, foetuses, or non-human animals such as companion = animals or farm animals. Deadline: = February 1st. Information about the call for = submissions can be found here: https://easst2022.org/callforsubmissions.asp and the full = abstract here: https://easst2022.org/IMAGENES/panelsResultados/004.pdfContact = person: violeta.argudo@csic.es (Violeta Argudo-Portal).With best = wishes,Violeta Argudo-Portal and Mauro = Turrini

=

--Apple-Mail=_A7BB10FE-EE25-4115-9CD8-977ED7947FC6--